Clinical trials: Pituitary
Growth Hormone Deficiency
Evolution Of Growth Rate In Children With Growth Retardation Due to Glucocorticosteroid Therapy And Treated By Genotonorm
To estimate the evolution of height and growth rate over 5 years of growth hormone (GH) treatment To estimate the prognostic factors of growth rate with GH treatment To confirm the good clinical and biological safety of GH…
- Trial name
- NCT00163189
- Testing
- Somatropin
- Where
- 19 sites in France
- Volunteers
- 98 people
- Sponsor
- Pfizer
Hypogonadism, Diabetes
Effects of Aromatase Inhibition Versus Testosterone in Older Men With Low Testosterone: Randomized-Controlled Trial.
Background: Men≥65 years often produce lower levels of testosterone, meaning there is less testosterone circulating to the tissues of the body.
- Conditions
- Hypogonadism, Diabetes, Sarcopenia, Osteoporosis
- Trial name
- NCT00104572
- Testing
- Androgel (Testosterone Gel), Anastrozole (Aromatase Inhibitor), Calcium Cardone 500mg with vitamin D 400 IU
- Where
- United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- National Institute on Aging (NIA)
Psoriasis Vulgaris
Effect of Calcipotriol Plus Hydrocortisone Ointment on the Adrenal Hormone Balance and Calcium Metabolism in Patients With Psoriasis Vulgaris on the Face and Skin Folds
There are few therapies suitable for the treatment of psoriasis on the face and skin folds. As these areas are sensitive, irritation and other adverse reactions are more common than elsewhere on the body.
- Trial name
- NCT00704262
- Testing
- Calcipotriol plus hydrocortisone (LEO 80190)
- Where
- 11 sites in United States, Canada and 2 more
- Volunteers
- 33 people
- Sponsor
- LEO Pharma
Cocaine Dependence
Investigation of Intranasal Oxytocin on Relapse Risk in Cocaine-dependent Patients.
This proposal describes a combined laboratory and clinical trial preliminary investigation to advance medication development for cocaine dependence.
- Trial name
- NCT02255357
- Testing
- Intranasal Oxytocin
- Where
- 2 sites in United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- New York State Psychiatric Institute
Growth Hormone Deficiency (GHD)
Saizen® Solution for Injection Adult Growth Hormone Deficiency (GHD) Immunogenicity Study
To assess the immunogenicity of Saizen® solution for injection in adult subjects with documented Growth Hormone Deficiency (GHD).
- Trial name
- NCT01237340
- Testing
- Saizen®
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- EMD Serono
Perennial Allergic Rhinitis
Study of the Effects of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol on Hypothalamic-Pituitary-Adrenal (HPA) Axis
To demonstrate the effects of ciclesonide applied as a nasal aerosol and ciclesonide aqueous (AQ) nasal spray on hypothalamic-pituitary-adrenal axis.
- Trial name
- NCT01033825
- Testing
- Ciclesonide HFA Nasal Aerosol 320 mcg, Ciclesonide HFA Nasal Aerosol 160 mcg, Ciclesonide Aqueous Nasal Spray 200 mcg
- Where
- 6 sites in United States
- Volunteers
- 310 people
- Sponsor
- Sumitomo Pharma America, Inc.
Acromegaly
Efficacy and Safety of Octreotide (MYCAPSSA™ [Formerly Octreolin™]) for Acromegaly
MYCAPSSA™ (formerly Octreolin™) is a proprietary oral form of the approved injectable medical product octreotide used to treat acromegaly.
- Trial name
- NCT01412424
- Testing
- Octreotide capsules
- Where
- 36 sites in United States, Germany and 11 more
- Volunteers
- 155 people
- Sponsor
- Chiasma, Inc.
Hypertension, End Stage Renal Disease
Study of the Effect of Intradialytic Vasopressin on Chronic Hypertension in Patients With End Stage Renal Disease
The death rate of patients with endstage renal disease (ESRD) on dialysis each year is 20%, with diseases related to the heart and blood vessels causing about half.
- Trial name
- NCT01247090
- Testing
- Vasopressin - Very Low Dose, Vasopressin - Low Dose
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Columbia University
Growth Hormone Deficiency, Pediatric, hGH (Human Growth Hormone)
A Phase 3 Trial of the Safety, Tolerability and Efficacy of TransCon hGH Weekly Versus Daily hGH in Children With Growth Hormone Deficiency (GHD)
A 52 week trial of TransCon hGH, a long-acting growth hormone product, versus human growth hormone therapy. TransCon hGH will be given once-a-week, human growth hormone (hGH) will be given daily.
- Conditions
- Growth Hormone Deficiency, Pediatric, hGH (Human Growth Hormone), Endocrine System Diseases, Hormones
- Trial name
- NCT02781727
- Testing
- Once weekly subcutaneous injection of TransCon hGH, Once daily subcutaneous injection of Genotropin
- Where
- 53 sites in United States, Armenia and 12 more
- Volunteers
- 162 people
- Sponsor
- Ascendis Pharma Endocrinology Division A/S
Acromegaly
A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly
A randomized, placebo-controlled study designed to evaluate the safety and efficacy of paltusotine (also known as CRN00808; an orally administered nonpeptide somatostatin agonist) in subjects with acromegaly previously treated…
- Trial name
- PATHFNDR-1 (NCT04837040)
- Testing
- Paltusotine
- Where
- 39 sites in United States, Argentina and 12 more
- Volunteers
- 58 people
- Sponsor
- Crinetics Pharmaceuticals Inc.
Acromegaly
Efficacy and Safety of Octreotide Capsules (MYCAPSSA) in Acromegaly
Octreotide capsule is a novel, orally-administered formulation of the commercially-available injectable drug octreotide. In a recent phase 3 trial, oral octreotide capsules demonstrated maintenance of biochemical response up to…
- Trial name
- OPTIMAL (NCT03252353)
- Testing
- octreotide capsules
- Where
- 60 sites in United States, Australia and 15 more
- Volunteers
- 56 people
- Sponsor
- Chiasma, Inc.
Acromegaly
Safety, Tolerability, and Efficacy of IONIS-GHR-LRx in Participants With Acromegaly Being Treated With Long-acting Somatostatin Receptor Ligands
The purpose of this study was to assess the safety, tolerability, and efficacy of IONIS-GHR-LRx in up to 60 participants with acromegaly.
- Trial name
- NCT03548415
- Testing
- IONIS-GHR-LRx
- Where
- 33 sites in United States, Hungary and 5 more
- Volunteers
- 43 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Clostridium Difficile Infection Recurrence
Efficacy, Safety, and Tolerability Study of Oral Full-Spectrum MicrobiotaTM (CP101) in Subjects With Recurrent C. Diff
Subjects with recurrent C. difficile infection will receive an oral dose of CP101 capsules one time in Treatment Group I or matching placebo one time in Treatment Group II.
- Trial name
- PRISM3 (NCT03110133)
- Testing
- Full Spectrum Microbiota
- Where
- 58 sites in United States, Canada
- Volunteers
- 206 people
- Sponsor
- Finch Research and Development LLC.
Acromegaly, Neuroendocrine Tumors
Phase II Study of Subcutaneous Inj. Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs)
This is a Phase II, open-label multicentre, randomised study to assess the PK, PD, efficacy, and safety of two dosing regimens of CAM2029 in adult patients with acromegaly or a functional, well-differentiated NET, with carcinoid…
- Trial name
- NCT02299089
- Testing
- octreotide FluidCrystal® injection depot
- Where
- 10 sites in France, Germany and 2 more
- Volunteers
- 12 people
- Sponsor
- Camurus AB
Diabetes Insipidus
Shared Health Appointments and Reciprocal Enhanced Support
The purpose of this study is to evaluate the effectiveness of a peer-to-peer program (P2P) in addition to Shared Medical Appointments (SMAs) compared to SMAs alone for the treatment of diabetes in five VA health systems, and to…
- Trial name
- SHARES (NCT02132676)
- Where
- 5 sites in United States
- Volunteers
- 1,536 people
- Sponsor
- VA Office of Research and Development
Acromegaly, Growth Hormone Deficiency
Effects of Growth Hormone Administration on Cardiovascular Risk in Cured Acromegalics With Growth Hormone Deficiency
The purpose of the study is to evaluate the effects of growth hormone (GH) replacement in men and women with a history of acromegaly and who are now growth hormone deficient.
- Conditions
- Acromegaly, Growth Hormone Deficiency, Pituitary Disease
- Trial name
- NCT00182091
- Testing
- Recombinant human growth hormone, Saline
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Massachusetts General Hospital
Hypopituitarism
Effects of Growth Hormone on Cognition and Cerebral Metabolism in Adults With Growth Hormone Deficiency
Patients with Growth hormone (GH) deficiency often report impaired quality of life and difficulty with mental functioning. It has been suggested that GH replacement in such patients leads to improvement in cognitive function.
- Trial name
- GHD (NCT01007071)
- Testing
- Human Growth Hormone (1-134)
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Stanford University
Adult Growth Hormone Deficiency
A Phase 3, Multicenter Study To Evaluate The Efficacy And Safety Of MOD-4023 In Adults With Growth Hormone Deficiency
This will be a randomized, double-blind, placebo-controlled, parallel-group, multicenter study in adult subjects with GHD to assess the safety and efficacy of a long-acting, once weekly injection of modified hGH (MOD-4023).
- Trial name
- NCT01909479
- Testing
- MOD-4023
- Where
- Israel
- Volunteers
- 202 people
- Sponsor
- OPKO Health, Inc.
Hypothalamic-pituitary-ovarian Axis, Gonadotropins, Ethinyl Estradiol, Contraceptive Efficacy
Oral Contraceptive Hormone-free Interval Pituitary/ Ovarian Activity
The degree of suppression and subsequent activation of the hypothalamic-pituitary-ovarian axis during the hormone-free interval in combined oral contraceptive (COC) hormone users varies depending on the dose of ethinyl estradiol…
- Trial name
- NCT01953211
- Testing
- combined oral contraceptives
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- University of Southern California
Cushing's Disease
Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease
This is a randomized, double-blind, multicenter, phase III study to evaluate the safety and efficacy of 2 dosing regiments of Pasireotide long acting release (LAR) in patients with Cushing's disease.
- Trial name
- NCT01374906
- Testing
- pasireotide LAR, SOM230 LAR 30 mg, SOM230 LAR 10 mg
- Where
- 82 sites in United States, Argentina and 18 more
- Volunteers
- 150 people
- Sponsor
- Novartis Pharmaceuticals